| Ytd | 26.84% | |
| 1y | -78.26% |
| Open | 10.60 | Prev Close | 10.58 | Low | 10.13 | High | 10.78 | Mkt Cap | 149.61M |
| Vol | 133.51K | Avg Vol | 148.86K | EPS | -9.50 | P/E | N/A | Forward P/E | -4.29 |
| Beta | 3.13 | Short Ratio | 2.64 | Inst. Own | 91.36% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 11-12 | 50-d Avg | 11.91 | 200-d Avg | 11.74 | 1yr Est | 137.76 |
KRRO News
HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Korro Bio (NASDAQ:KRRO) with a Buy
Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a clinical-stage biopharmaceutical company leveraging its ol
CAMBRIDGE, Mass., Oct. 05, 2026 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a clinic
Korro Bio, Inc. (NASDAQ: KRRO - Get Free Report) has received a consensus rating of "Moderate Buy" f
Gainers IM Cannabis (NASDAQ:IMCC) stock increased by 246.0% to $6.02 during Friday's regular se
CAMBRIDGE, Mass., Sept. 11, 2026 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a bioph
CAMBRIDGE, Mass., Aug. 27, 2026 (GLOBE NEWSWIRE) -- Korro, Bio, Inc. (Korro) (Nasdaq: KRRO), a bioph
Korro Bio, Inc. (NASDAQ: KRRO - Get Free Report) has received a consensus recommendation of "Moderat
HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Korro Bio (NASDAQ:KRRO) with a Buy
CAMBRIDGE, Mass., Aug. 14, 2026 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a biopha
Korro Bio, Inc. (KRRO) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about
Korro Bio (NASDAQ:KRRO) reported quarterly losses of $(1.07) per share which beat the analyst consen
KRRO-121, a potential first-in-class transformational treatment for hyperammonemia, remains on track
Enlivex Therapeutics (NASDAQ: ENLV - Get Free Report) and Korro Bio (NASDAQ: KRRO - Get Free Report)
CAMBRIDGE, Mass., July 10, 2026 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO) a biophar
Korro Bio, Inc. (KRRO) might move higher on growing optimism about its earnings prospects, which is
Korro Bio, Inc. (KRRO) was a big mover last session on higher-than-average trading volume. The lates
CAMBRIDGE, Mass., May 27, 2026 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a biophar
Potential best-in-class therapeutic delivered subcutaneously (GalNAc-conjugated oligonucleotide) for
Potential best-in-class therapeutic delivered subcutaneously (GalNAc-conjugated oligonucleotide) for
HC Wainwright & Co. analyst Mitchell S. Kapoor maintains Korro Bio (NASDAQ:KRRO) with a Buy a
Citigroup analyst Yigal Nochomovitz initiates coverage on Korro Bio (NASDAQ:KRRO) with a Buy rati
CAMBRIDGE, Mass., May 15, 2026 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a biophar
Korro Bio (NASDAQ:KRRO) reported quarterly losses of $(1.69) per share which beat the analyst consen
Hosted virtual Analyst Day showcasing lead program KRRO-121's potential to be a first-in-class trans
CAMBRIDGE, Mass., May 05, 2026 (GLOBE NEWSWIRE) -- Korro, Bio, Inc. (Korro) (Nasdaq: KRRO), a biopha
Korro Bio, Inc. (KRRO) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about
Shares of Korro Bio, Inc. (NASDAQ: KRRO - Get Free Report) have earned an average rating of "Moderat
CAMBRIDGE, Mass., April 16, 2026 (GLOBE NEWSWIRE) -- Korro, Bio, Inc. (Korro) (Nasdaq: KRRO), a bio
